Related Experiment Video
Updated: Apr 14, 2026
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma
De-Chen Lin1, Liang Xu2, Ye Chen2
1Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. dchlin11@gmail.com yin_dong@yahoo.com.
Abstract:
PARK2 (PARKIN) is an E3 ubiquitin ligase whose dysfunction has been associated with the progression of Parkinsonism and human malignancies, and its role in cancer remains to be explored. In this study, we report that PARK2 is frequently deleted and underexpressed in human glioma, and low PARK2 expression is associated with poor survival. Restoration of PARK2 significantly inhibited glioma cell growth both in vitro and in vivo, whereas depletion of PARK2 promoted cell proliferation. PARK2 attenuated both Wnt- and EGF-stimulated pathways through downregulating the intracellular level of β-catenin and EGFR. Notably, PARK2 physically interacted with both β-catenin and EGFR. We further found that PARK2 promoted the ubiquitination of these two proteins in an E3 ligase activity-dependent manner. Finally, inspired by these newly identified tumor-suppressive functions of PARK2, we tested and proved that combination of small-molecule inhibitors targeting both Wnt-β-catenin and EGFR-AKT pathways synergistically impaired glioma cell viability. Together, our findings uncover novel cancer-associated functions of PARK2 and provide a potential therapeutic approach to treat glioma.
Insights
PARK2 (PARKIN) acts as a tumor suppressor in glioma by inhibiting cell growth and proliferation. Restoring PARK2 function offers a potential therapeutic strategy for glioma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- PARK2 (PARKIN) is an E3 ubiquitin ligase implicated in Parkinsonism and cancer.
- Its specific role in human glioma and its oncogenic or tumor-suppressive functions were largely unexplored.
Purpose of the Study:
- To investigate the role of PARK2 in human glioma.
- To elucidate the molecular mechanisms underlying PARK2's function in glioma.
- To explore potential therapeutic strategies targeting PARK2 pathways.
Main Methods:
- Analysis of PARK2 deletion and expression in human glioma tissues.
- In vitro and in vivo experiments assessing the effects of PARK2 restoration and depletion on glioma cell growth.
- Investigation of PARK2's interaction with Wnt/β-catenin and EGFR/AKT pathways.
- Ubiquitination assays to determine PARK2's enzymatic activity.
- Combination therapy studies using small-molecule inhibitors.
Main Results:
- PARK2 is frequently deleted and underexpressed in human glioma, correlating with poor patient survival.
- PARK2 restoration inhibited glioma cell proliferation, while its depletion promoted it.
- PARK2 attenuated Wnt and EGF signaling by downregulating β-catenin and EGFR through ubiquitination.
- Combined inhibition of Wnt-β-catenin and EGFR-AKT pathways synergistically reduced glioma cell viability.
Conclusions:
- PARK2 exhibits significant tumor-suppressive functions in glioma.
- PARK2 regulates glioma progression by targeting key oncogenic pathways.
- Targeting PARK2-associated pathways presents a promising therapeutic avenue for glioma.
